Immunotherapy for cutaneous malignancy

Dermatologic Surgery

Volumn 37, Issue 10, 2011, Pages 1377-1393

  Ibrahim, Sherrif F ^a,b   Sambandan, Divya ^b   Ratner, Désirée ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BEVACIZUMAB; CPG OLIGODEOXYNUCLEOTIDE; CYCLIN DEPENDENT KINASE 4; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA VACCINE; FLUDARABINE; GLYCOPROTEIN GP 100; IMIQUIMOD; INTERLEUKIN 2; IPILIMUMAB; MELAN A; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TRASTUZUMAB; WART VIRUS VACCINE;

ACTINIC KERATOSIS; ADOPTIVE TRANSFER; ADVANCED CANCER; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; BASAL CELL CARCINOMA; BCG VACCINATION; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PREVENTION; CANCER REGRESSION; CANCER RISK; CD8+ T LYMPHOCYTE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMPETITIVE INHIBITION; CYTOKINE PRODUCTION; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; KERATINOCYTE; LUNG METASTASIS; LYMPHOCYTE SUBPOPULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDLINE; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; ULTRAVIOLET RADIATION; UTERINE CERVIX CANCER;

ADOPTIVE TRANSFER; ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN; SKIN NEOPLASMS;

EID: 80053897166     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2011.02070.x     Document Type: Review

References (133)

1. Hunder NN, Wallen H, Cao J, Hendricks DW, et al,. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-703.
2. Lembo S, Fallon J, O'Kelly P, Murphy GM., Polymorphic light eruption and skin cancer prevalence: is one protective against the other? Br J Derm 2008; 159: 1342-7.
3. Jack A, Boyes C, Aydin N, Alam K, et al,. The treatment of melanoma with an emphasis on immunotherapeutic strategies. Surg Oncol 2006; 15: 13-24.
4. Vogt A, Chuang PT, Hebert J, Hwang J, et al,. Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein. J Exp Med 2004; 199: 753-61.
5. Aftergut K, Curry M, Cohen J., Candida antigen in the treatment of basal cell carcinoma. Dermatol Surg 2005; 31: 16-8.
6. Sauder DN., The emerging role of immunotherapy in the treatment of non-melanoma skin cancers. Nat Clin Pract Oncol 2005; 2: 326-7.
7. Gaspari AA, Sauder DN., Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg 2003; 29: 1027-34.
8. Urosevic M, Dummer R., Immunotherapy for nonmelanoma skin cancer: does it have a future? Cancer 2002; 94: 477-85.
9. Coley WB., Contribution to the study of sarcoma of the femur: periosteal round-celled sarcoma of the femur, involving two-thirds of the shaft, with very extensive multiple metastases-apparent cure by the mixed toxins of Erysipelas and Bacillus Prodigiosus. Ann Surg 1913; 58: 97-108.
10. Coley WB., Contribution to the knowledge of Sarcoma. Ann Surg 1891; 14: 199-220.
11. Morton DL, Eilber FR, Holmes EC, Hunt JS, et al,. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 1974; 180: 635-43.
12. Burnet FM., The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
13. Toews GB, Bergstresser PR, Streilein JW., Langerhans cells: sentinels of skin associated lymphoid tissue. J Invest Dermatol 1980; 75: 78-82.
14. Bos JD, Zonneveld I, Das PK, Krieg SR, et al,. The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. J Invest Dermatol 1987; 88: 569-73.
15. Morton DL, Malmgren RA, Holmes EC, Ketcham AS., Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 1968; 64: 233-40.
16. Mukherji B, Wilhelm SA, Guha A, Ergin MT., Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 1986; 136: 1888-92.
17. Fairley GH, Lewis MG, Ikonopisov RL, Nairn RC, et al,. Detection of tumor specific immune reactions in human melanoma. Ann N Y Acad Sci 1971; 177: 286-9.
18. Nairn RC, Guli EP, Nind AP, Muller HK, et al,. Specific immune response in human skin carcinoma. Br Med J 1971; 4: 701-5.
19. Shankaran V, Ikeda H, Bruce AT, White JM, et al,. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
20. Chiao EY, Krown SE., Update on non-acquired immunodeficiency syndrome-defining malignancies. Curr Opin Oncol 2003; 15: 389-97.
21. Woods GM, Malley RC, Muller HK., The skin immune system and the challenge of tumour immunosurveillance. Eur J Dermatol 2005; 15: 63-9.
22. McGovern VJ., Spontaneous regression of melanoma. Pathology 1975; 7: 91-9.
23. Curson C, Weedon D., Spontaneous regression in basal cell carcinomas. J Cutan Pathol 1979; 6: 432-7.
24. Oram Y, Orengo I, Griego RD, Rosen T, et al,. Histologic patterns of basal cell carcinoma based upon patient immunostatus. Dermatol Surg 1995; 21: 611-4.
25. McArdle JP, Knight BA, Halliday GM, Muller HK, et al,. Quantitative assessment of Langerhans cells in actinic keratosis, Bowen's disease, keratoacanthoma, squamous cell carcinoma and basal cell carcinoma. Pathology 1986; 18: 212-6.
26. Ladányi A, Kiss J, Somlai B, Gilde K, et al,. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007; 56: 1459-69.
27. Ram M, Shoenfeld Y., Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann N Y Acad Sci 2007; 1110: 410-25.
28. Baldi A, Dragonetti E, Battista T, Groeger AM, et al,. Detection of circulating malignant cells by RT-PCR in long-term clinically disease-free I stage melanoma patients. Anticancer Res 2000; 20: 3923-8.
29. Kovach BT, Stasko T., Skin cancer after transplantation. Transplant Rev (Orlando) 2009; 23: 178-89.
30. Singh M, Lin J, Hocker TL, Tsao H., Genetics of melanoma tumorigenesis. Br J Dermatol 2008; 158: 15-21.
31. Tsao H, Atkins MB, Sober AJ., Management of cutaneous melanoma. N Engl J Med 2004; 351: 998-1012.
32. Kadison AS, Morton DL., Immunotherapy of malignant melanoma. Surg Clin North Am 2003; 83: 343-70.
33. Adema GJ, de Boer AJ, Vogel AM, Loenen WA, et al,. Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem 1994; 269: 20126-33.
34. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, et al,. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994; 91: 6458-62.
35. Vourc'h-Jourdain M, Volteau C, Nguyen JM, Khammari A, et al,. Melanoma gene expression and clinical course. Arch Dermatol Res 2009; 301: 673-9.
36. Ries J, Vairaktaris E, Mollaoglu N, Wiltfang J, et al,. Expression of melanoma-associated antigens in oral squamous cell carcinoma. J Oral Pathol Med 2008; 37: 88-93.
37. Goldstein AM, Struewing JP, Fraser MC, Smith MW, et al,. Prospective risk of cancer in CDKN2A germline mutation carriers. J Med Genet 2004; 41: 421-4.
38. Merad M, Manz MG, Karsunky H, Wagers A, et al,. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 2002; 3: 1135-41.
39. Picker LJ., Control of lymphocyte homing. Curr Opin Immunol 1994; 6: 394-406.
40. Paul WE., Dendritic cells bask in the limelight. Cell 2007; 130: 967-70.
41. Prestwich RJ, Errington F, Hatfield P, Merrick AE, et al,. The immune systema - is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol) 2008; 20: 101-12.
42. Dunn GP, Old LJ, Schreiber RD., The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48.
43. Polak ME, Borthwick NJ, Gabriel FG, Johnson P, et al,. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 2007; 96: 1879-87.
44. Dreiling L, Hoffman S, Robinson WA., Melanoma: epidemiology, pathogenesis, and new modes of treatment. Adv Intern Med 1996; 41: 553-604.
45. Balch CM, Buzaid AC, Soong SJ, Atkins MB, et al,. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
46. Essner R, Lee JH, Wanek LA, Itakura H, et al,. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 2004; 139: 961-6.
47. Wong SL, Coit DG., Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 2004; 16: 155-60.
48. Hsueh EC, Gupta RK, Yee R, Leopoldo ZC, et al,. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann Surg Oncol 2000; 7: 232-8.
49. Boon T, Gajewski TF, Coulie PG., From defined human tumor antigens to effective immunization? Immunol Today 1995; 16: 334-6.
50. Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, et al,. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005; 11: 107-12.
51. Andersen MH, Gehl J, Reker S, Pedersen LÃ, et al,. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 2003; 13: 449-59.
52. Chen Q, Daniel V, Maher DW, Hersey P., Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994; 56: 755-60.
53. Conrad CT, Ernst NR, Dummer W, Bröcker EB, et al,. Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J Exp Clin Cancer Res 1999; 18: 225-32.
54. Hunt MJ, Halliday GM, Weedon D, Cooke BE, et al,. Regression in basal cell carcinoma: an immunohistochemical analysis. Br J Dermatol 1994; 130: 1-8.
55. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, et al,. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-64.
56. Dieckmann D, Plottner H, Berchtold S, Berger T, et al,. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303-10.
57. Baumgartner J, Wilson C, Palmer B, Richter D, et al,. McCarter M Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res 2007; 141: 72-7.
58. Norval M., The mechanisms and consequences of ultraviolet-induced immunosuppression. Prog Biophys Mol Biol 2006; 92: 108-18.
59. de Gruijl FR., UV-induced immunosuppression in the balance. Photochem Photobiol 2008; 84: 2-9.
60. Kripke ML, Lofgreen JS, Beard J, Jessup JM, et al,. In vivo immune responses of mice during carcinogenesis by ultraviolet irradiation. J Natl Cancer Inst 1977; 59: 1227-30.
61. Hart PH, Townley SL, Grimbaldeston MA, Khalil Z, et al,. Mast cells, neuropeptides, histamine, and prostaglandins in UV-induced systemic immunosuppression. Methods 2002; 28: 79-89.
62. Yoshikawa T, Rae V, Bruins-Slot W, Van den Berg JW, et al,. Susceptibility to effects of UVB radiation on induction of contact hypersensitivity as a risk factor for skin cancer in humans. J Invest Dermatol 1990; 95: 530-6.
63. Schwarz A, Schwarz T., Molecular determinants of UV-induced immunosuppression. Exp Dermatol 2002; 11 (Suppl 1): 9-12.
64. Damian DL, Patterson CR, Stapelberg M, Park J, et al,. UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol 2008; 128: 447-54.
65. Wheatley K, Ives N, Hancock B, Gore M, et al,. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29: 241-52.
66. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, et al,. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-58.
67. Agarwala SS, Kirkwood JM., Interferons in melanoma. Curr Opin Oncol 1996; 8: 167-74.
68. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, et al,. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14: 2666-73.
69. Lens MB, Dawes M., Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20: 1818-25.
70. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, et al,. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-16.
71. Keilholz U, Conradt C, Legha SS, Khayat D, et al,. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16: 2921-9.
72. Bottomley A, Coens C, Suciu S, Santinami M, et al,. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009; 27: 2916-23.
73. Atkins MB., Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006; 12 (7 Pt 2): 2353s-8s.
74. Isaacs A, Lindenmann J., Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-67.
75. Bart RS, Porzio NR, Kopf AW, Vilcek JT, et al,. Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Cancer Res 1980; 40: 614-9.
76. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, et al,. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
77. Greenway HT, Cornell RC, Tanner DJ, Peets E, et al,. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 1986; 15: 437-43.
78. Kirby JS, Miller CJ., J Am Acad Dermatol 2010 Oct; 63 (4): 689-702. Epub 2010 Jun.
79. Rosenberg SA, Lotze MT, Muul LM, Leitman S, et al,. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-92.
80. Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, et al,. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161: 1169-88.
81. Miller LS., Toll-like receptors in skin. Adv Dermatol 2008; 24: 71-87.
82. Neville JA, Welch E, Leffell DJ., Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol 2007; 4: 462-9.
83. Ahmed I, Berth-Jones J., Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000; 143: 843-5.
84. Wolf IH, Smolle J, Binder B, Cerroni L, et al,. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003; 139: 273-6.
85. Warshauer E, Warshauer BL., Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy. J Drugs Dermatol 2008; 7: 447-51.
86. Krieg AM., Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004; 6: 88-95.
87. Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, et al,. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 2003; 171: 3941-6.
88. Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, et al,. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 739-46.
89. Mazzoni A, Segal DM., Controlling the Toll road to dendritic cell polarization. J Leukoc Biol 2004; 75: 721-30.
90. Pardoll D, Allison J., Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 2004; 10: 887-92.
91. Baselga J, Tripathy D, Mendelsohn J, Baughman S, et al,. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-44.
92. Marwick C., Monoclonal antibody to treat lymphoma. JAMA 1997; 278: 616-8.
93. Willett CG, Boucher Y, di Tomaso E, Duda DG, et al,. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7.
94. Dadachova E, Revskaya E, Sesay MA, Damania H, et al,. Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther 2008; 7: 1116-27.
95. Terheyden P, Hofmann MA, Weininger M, Bröcker EB, et al,. Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. J Cancer Res Clin Oncol 2007; 133: 897-901.
96. Varker KA, Biber JE, Kefauver C, Jensen R, et al,. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007; 14: 2367-76.
97. Gross JA, Callas E, Allison JP., Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol 1992; 149: 380-8.
98. Alegre ML, Frauwirth KA, Thompson CB., T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1: 220-8.
99. Linsley PS, Greene JL, Brady W, Bajorath J, et al,. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1: 793-801.
100. Lindsten T, Lee KP, Harris ES, Petryniak B, et al,. Characterization of CTLA-4 structure and expression on human T cells. J Immunol 1993; 151: 3489-99.
101. Lenschow DJ, Walunas TL, Bluestone JA., CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-58.
102. Waterhouse P, Penninger JM, Timms E, Wakeham A, et al,. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985-8.
103. Camacho LH, Antonia S, Sosman J, Kirkwood JM, et al,. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009; 27: 1075-8.
104. Reuben JM, Lee BN, Li C, Gomez-Navarro J, et al,. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006; 106: 2437-44.
105. Wolchok JD, Saenger Y., The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008; 13 (Suppl 4): 2-9.
106. Phan GQ, Yang JC, Sherry RM, Hwu P, et al,. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100: 8372-7.
107. Hodi FS, Butler M, Oble DA, Seiden MV, et al,. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008; 105: 3005-10.
108. Maker AV, Phan GQ, Attia P, Yang JC, et al,. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12: 1005-16.
109. Tomihara K, Kato K, Masuta Y, Nakamura K, et al,. Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells. Gene Ther 2008; 15: 203-13.
110. Terando AM, Faries MB, Morton DL., Vaccine therapy for melanoma: current status and future directions. Vaccine 2007; 25 (Suppl 2): B4-16.
111. Koutsky LA, Ault KA, Wheeler CM, Brown DR, et al,. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51.
112. Finn OJ, Forni G., Prophylactic cancer vaccines. Curr Opin Immunol 2002; 14: 172-7.
113. Rosenberg SA, Yang JC, Restifo NP., Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
114. Ridgway D., The first 1000 dendritic cell vaccinees. Cancer Invest 2003; 21: 873-86.
115. Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, et al,. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 2008; 66: 118-34.
116. O'Rourke MG, Johnson MK, Lanagan CM, See JL, et al,. Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res 2007; 17: 316-22.
117. El Marsafy S, Bagot M, Bensussan A, Mauviel A., Dendritic cells in the skina - potential use for melanoma treatment. Pigment Cell Melanoma Res 2009; 22: 30-41.
118. Rosenberg SA., Shedding light on immunotherapy for cancer. N Engl J Med 2004; 350: 1461-3.
119. Ali OA, Huebsch N, Cao L, Dranoff G, et al,. Infection-mimicking materials to program dendritic cells in situ. Nat Mater 2009; 8: 151-8.
120. Yee C, Thompson JA, Byrd D, Riddell SR, et al,. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002; 99: 16168-73.
121. Ho WY, Blattman JN, Dossett ML, Yee C, et al,. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003; 3: 431-7.
122. Dudley ME, Rosenberg SA., Adoptive cell transfer therapy. Semin Oncol 2007; 34: 524-31.
123. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, et al,. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86: 1159-66.
124. Dudley ME, Wunderlich JR, Yang JC, Hwu P, et al,. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002; 25: 243-51.
125. Huang J, Khong HT, Dudley ME, El-Gamil M, et al,. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 2005; 28: 258-67.
126. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, et al,. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-57.
127. Goldrath AW, Bogatzki LY, Bevan MJ., Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 2000; 192: 557-64.
128. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, et al,. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 2007; 13 (18 Pt 1): 5280-9.
129. Fang L, Lonsdorf AS, Hwang ST., Immunotherapy for advanced melanoma. J Invest Dermatol 2008; 128: 2596-605.
130. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, et al,. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308.
131. Marshall JA, Forster TH, Purdie DM, Lanagan CM, et al,. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. Immunol Cell Biol 2006; 84: 295-302.
132. Tímár J, Mészáros L, Ladányi A, Puskás LG, et al,. Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies. Cell Immunol 2006; 244: 154-7.
133. Tilli CM, Van Steensel MA, Krekels GA, Neumann HA, et al,. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol 2005; 152: 1108-24.